Lung cancer trial questions need for immediate brain radiation in asymptomatic patients

NCT ID NCT05236946

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This Phase 3 trial is testing whether it is safe to delay brain radiotherapy in lung cancer patients with specific genetic mutations (EGFR/ALK) who have asymptomatic brain metastases. Participants will receive standard targeted therapy (TKI) and be randomly assigned to either immediate brain radiation or observation with radiation only if symptoms develop. The study aims to see if delaying radiation can maintain brain tumor control while avoiding unnecessary side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Tyrosine kinase inhibitor (TKI) and brain radiotherapy (stereotactic radiosurgery or whole brain radiotherapy)

What this could lead to

If successful, this could show that delaying brain radiotherapy is safe for patients with asymptomatic brain metastases, allowing them to avoid side effects while still controlling the disease.

What could go wrong

This is a relatively small Phase 3 trial (190 participants) and results may not apply to all lung cancer types. There is a risk that delaying radiotherapy could lead to worse brain tumor control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASYMPTOMATIC BRAIN METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Tata Memorial Hospital

    RECRUITING

    Mumbai, Maharashtra, 400012, India

    Contact Email: •••••@•••••

    Contact